Risk factors
Pliant Therapeutics (PLRX) risk factors
Item 1A of every Pliant Therapeutics, Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
84 risks, 15 new, 9 dropped, 25 reworded since the prior year. Discontinuation of the BEACON-IPF Phase 2b trial for bexotegrast drove major restructuring, cost reduction, and strategic alternatives.
Filed Mar 11, 2026 - FY2024 10-K risk factors
78 risks. Clinical stage biopharmaceutical company focused on discovering and developing treatments for fibrotic diseases, primarily dependent on lead candidate bexotegrast.
Filed Mar 03, 2025